

## Press Release

# Eurofins Genomics Europe Announces Strategic Relocation and Expansion of NGS Services Across Europe

Ebersberg, Germany – 11.08.2025

Eurofins Genomics Europe, a leading provider of genomic services and solutions, has announced the strategic relocation of its Next Generation Sequencing (NGS) operations from Constance to Ebersberg, Germany. This move is part of the company's broader initiative to enhance operational efficiency, expand service capacity, and strengthen its presence across Europe.

The relocation is designed to streamline workflows and enhance service delivery through greater flexibility and responsiveness. The transition is scheduled for Q4 of 2025, with completion expected by 31 December 2025. During this period, Eurofins Genomics Europe will guarantee uninterrupted support for all ongoing projects and partnerships, ensuring continuity of service for customers.

By consolidating advanced NGS technologies with a wide range of complementary services—including nucleic acid extraction, PCR, Sanger sequencing, applied food and environmental DNA testing, as well as oligonucleotide and gene synthesis—Eurofins Genomics Europe is establishing a uniquely comprehensive genomics ecosystem at its Ebersberg site. This integrated environment is designed to support high-quality, end-to-end genomic analysis, backed by industry-leading quality standards (GLP, GCP, ISO 17025, ISO 13485) and expert scientific teams.

In parallel with the relocation to Ebersberg, Eurofins Genomics Europe is expanding its NGS service offering to two additional strategic locations: the United Kingdom and Denmark. This expansion strengthens the company's infrastructure and geographic footprint, enabling faster, more localised support and improved turnaround times for customers across Europe. Whether for individual sample analysis or large-scale, high-throughput projects, this strategic move enhances flexibility and ensures a more responsive service tailored to diverse sequencing needs.

Eurofins Genomics Europe's NGS portfolio encompasses all leading platforms in the industry, supporting a broad spectrum of applications with both short- and long-read technologies. In response to growing market demand, the company continues to expand its integrated solutions across genomics and proteomics to meet the evolving needs of the research, pharmaceutical, clinical, environmental, food, and agrigenomics sectors throughout Europe.

### Key benefits of the expansion include:

- Designed to increase flexibility and responsiveness to customer needs
- Scalable sequencing solutions for projects of all sizes, using a variety of NGS technologies
- Enhanced access to expanded European infrastructure with integrated genomics and proteomics offerings
- Access to a robust and comprehensive service platform that supports everything from early discovery to regulated applications
- Seamless continuity of service during the transition

Eurofins Genomics Europe remains dedicated to advancing scientific discovery through innovation, quality, and customer-focused service.

For further information please contact:

Julian Schloßmacher

Head of Marketing and Communication Eurofins Genomics Europe

[julian.schlossmacher@genomics.eurofinseu.com](mailto:julian.schlossmacher@genomics.eurofinseu.com)

<https://eurofinsgenomics.com>

#### About Eurofins Genomics:

Eurofins Genomics represents the genomic division within the Eurofins Scientific Group. With facilities in Europe, the United States and Asia, Eurofins Genomics is an internationally leading provider of DNA sequencing and genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, population genomics, consumer genomics, food, agriculture, biotechnological and research markets. The European branch is headquartered in Ebersberg, Germany. For further information, please visit [www.eurofinsgenomics.com](http://www.eurofinsgenomics.com)

#### About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Scientific SE shares are listed on Euronext Paris Stock Exchange.